Tenax Therapeutics Names Christopher Giordano To Succeed Anthony DiTonno As CEO - Quick Facts

(RTTNews) - Specialty pharmaceutical company Tenax Therapeutics, Inc. (TENX) announced Wednesday the appointment of Christopher Giordano to serve as Chief Executive Officer and a Director of the Company, effective July 14, 2021. He will succeed Anthony DiTonno, who will retire on July 13, 2021 following a successful decade of service with the Company.

From July 6, 2021 through July 14, 2021, Giordano will serve as an employee of the Company to assist with the smooth transition of DiTonno's duties.

Giordano, age 47, brings more than 20 years of experience in the clinical research industry. He most recently served as President of IQVIA Biotech and IQVIA MedTech since March 2018.

Giordano has been involved in the pharmaceutical development industry since 1998. In January 2001, he joined PPD, another global clinical research organization, in a sales role. Over the next seven years, he grew into increasing operational responsibility, and in August 2008 transitioned to Quintiles as a Vice President.

He served in roles of increasing responsibility at Quintiles, being appointed Global Vice President of the cardiovascular, renal, and metabolic group in February 2016, a position he held until his appointment as President of IQVIA Biotech and IQVIA MedTech.